ClinicalTrialsFinder
RecruitingPhase 2NCT07654140

A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Uncontrolled Hypertension

Sponsor

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Enrollment

252 participants

Start Date

Dec 9, 2025

Study Type

INTERVENTIONAL

Conditions

Uncontrolled Hypertension

Summary

This is a multicenter, randomized, double-blind, placebo-controlled phase II study designed to explore the efficacy and safety of different doses of SAL0140 in uncontrolled hypertension.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria6

  • Patients 18-75 years old, male or female.
  • Mean seated systolic blood pressure (msSBP) at screening was ≥140 mmHg and <180 mmHg.
  • Meet either item A or B at screening: A. Uncontrolled hypertension (uHTN); B. Resistant hypertension (rHTN).
  • Mean seated systolic blood pressure (msSBP) prior to randomization was ≥140 mmHg and <180 mmHg.
  • Voluntarily participate in this study and sign the informed consent form.
  • Agree to comply with contraception and fertility restrictions of this study.

Exclusion Criteria12

  • Severe hypertension (msSBP ≥ 180 mmHg and/or msDBP ≥ 110 mmHg); malignant hypertension, hypertensive emergency, hypertensive crisis, hypertensive encephalopathy, etc.
  • Compliance with study drug during the run-in period was less than 80% or greater than 120%.
  • Hypertension complicated with the following conditions: acute coronary syndrome, myocardial infarction, percutaneous coronary intervention, stroke.
  • Positive results for any of human immunodeficiency virus antibody (HIV), hepatitis C virus antibody (HCV), treponema pallidum antibody (TP); or positive hepatitis B surface antigen (HBsAg) with HBVDNA ≥ 1000 IU/mL.
  • Patients with active malignant tumors.
  • Patients receiving hemodialysis or adhering to strict salt restriction therapy.
  • History of adrenal insufficiency.
  • History of solid organ or bone marrow transplantation.
  • Gastrointestinal diseases or post-gastrointestinal surgery.
  • Known or suspected hypersensitivity to aldosterone synthase inhibitors; known or suspected contraindications or hypersensitivity to background medications.
  • History of drug abuse or alcohol abuse.
  • Blood donation or significant blood loss.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSAL0140

SAL0140 Tablets

DRUGSAL0140

SAL0140 Tablets

DRUGSAL0140

SAL0140 Tablets

DRUGPlacebo

Placebo

Locations(1)

Beijing Anzhen Hospital Capital Medical University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07654140

Related Trials

Wearable Evaluation of Ambulatory Readings for Blood Pressure

NCT066104481 location

Remote Hypertension Management for Black Patients

NCT065277941 location

Sequential Multiple Assignment Randomized Trial to Reduce Food Insecurity

NCT070317391 location

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

NCT0714235620 locations

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

NCT0709016128 locations